H. Lundbeck: Initiation of Coverage- Game-Changing Pipeline Poised to Redefine Neurological Treatments! 

H. Lundbeck A/S, a global pharmaceutical company specializing in brain disorders, reported robust performance for the first quarter of 2025. The results underscore the company’s progress in executing its strategic initiatives focused on innovation and strategic brand growth. Financially, Lundbeck posted a strong start to 2025, with total revenue increasing by 16% at constant exchange rates, reaching DKK 6.2 billion. This growth was primarily driven by a 24% rise in revenue from strategic brands, which now constitute 77% of total revenue. Key drivers included the migraine treatment Vyepti, which delivered a 62% growth, and the antipsychotic Rexulti, which grew by 28%, notably in the United States and select international markets. The adjusted EBITDA rose by 24% to DKK 2.2 billion, reflecting a robust operating margin of 34.9%, thanks to operating leverage and cost discipline.